Surrozen Change in Assets/Liabilities 2021-2025 | SRZN

Surrozen change in assets/liabilities from 2021 to 2025. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities

Surrozen Change in Assets/Liabilities 2021-2025 | SRZN

Surrozen change in assets/liabilities from 2021 to 2025. Change in assets/liabilities can be defined as represents any other changes in assets/liabilities
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$70.1B
Zoetis (ZTS)$68.6B
Takeda Pharmaceutical (TAK)$47.3B
Daiichi Sankyo, - (DSNKY)$46.4B
BeOne Medicines - (ONC)$33.9B
Sandoz Group AG (SDZNY)$27.3B
Summit Therapeutics (SMMT)$20B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$14.6B
United Therapeutics (UTHR)$13.9B
Neurocrine Biosciences (NBIX)$13.6B
Orion OYJ (ORINY)$11.3B
IPSEN (IPSEY)$11.1B
Madrigal Pharmaceuticals (MDGL)$9.4B
Eisai (ESAIY)$9.2B
Corcept Therapeutics (CORT)$7.3B
Grifols, S.A (GRFS)$6.8B
Ionis Pharmaceuticals (IONS)$6.7B
Stevanato Group S.p.A (STVN)$6.6B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.9B
Crinetics Pharmaceuticals (CRNX)$2.9B
NewAmsterdam Pharma (NAMS)$2.8B
Hypermarcas (HYPMY)$2.8B
Catalyst Pharmaceuticals (CPRX)$2.4B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.1B
Dyne Therapeutics (DYN)$1.9B